GSK (GSK) has pulled its application for the drug leucovorin calcium, which was touted last year by President Trump as a possible treatment for autism symptoms, just months after the drug maker submitted it at the request of health officials, the Wall Street Journal’s Liz Essley Whyte reports. The company asked the FDA to withdraw its application for the drug because it doesn’t market the medicine, the author says.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces China’s NMPA approved Exdensur as add-on therapy
- GSK’s New Cancer Drug GSK5533524 Enters First‑in‑Human Testing: What Investors Should Watch
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports
- White House says imposing tariffs on patented pharmaceutical products
- Trump Trade: President says Iran war will still take weeks